Venn Life Sciences Holdings PLC Senior Management Appointment (9357L)
July 25 2017 - 2:01AM
UK Regulatory
TIDMVENN
RNS Number : 9357L
Venn Life Sciences Holdings PLC
25 July 2017
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Senior Management Appointment
Venn Life Sciences (AIM: VENN), a growing Contract Research
Organisation providing drug development, clinical trial management
and resourcing solutions to pharmaceutical, biotechnology and
medical device clients, announces the appointment of Dr. Christian
Bernard Milla, aged 55, as Chief Operating Officer ('COO'), a Board
appointment, with effect from 16(th) August 2017.
At the same time Gracielle Schutjens, formely Chief Operations
Officer, will step down from the Board and assume a new role of
Business Development Director.
Christian is an experienced COO with a successful record of
delivering operational excellence in growing Clinical Research
Organisations, as well as driving revenue generation and business
growth.
Christian joins Venn from Oncodesign Biotechnology, a leader in
preclinical evaluations for anticancer, based in France, where he
was Chief Operating Officer. He was also a Board member of
Cromsource, a provider of outsourced services to the
pharmaceutical, biotechnology and medical device industries. From
2004 until 2007 Christian was CEO of OSMO Accovion SA, a niche
Oncology Site Management and CRO. Prior to this he held roles with
Parexel, Staticon International and Abbott Laboratories.
Christian will operate from the Venn offices in Paris. He is a
French citizen and has a PhD in Neurosiences from the University of
Paris.
A list of directorships, both current and in the past five years
is included below. Christian does not currently own any Venn shares
and confirms that there are no other items requiring disclosure in
accordance with Schedule 2(G)(iii) to (Viii) of the AIM Rules and
the ESM Rules.
Tony Richardson, Chief Executive Officer of Venn said: "I'm
delighted that Christian is joining our team at Venn and we're
confident that his operational expertise will ensure that we build
on the momentum created in 2016 whilst driving further growth both
organically and through acquisition going forward.
"Gracielle has made a considerable contribution to our
organisation combining both her COO activities with those of
business development. Given her successful delivery of significant
new business to the Company to date, we are confident that a
singular focus on the Business Development side of her role will
pay dividends for Venn."
Current Directorships Directorships in the last five
Milla Projects Consulting SARL years
PhenoPups SAS
Cromsource
Milla Projects Consulting SARL
-------------------------------- --------------------------------
Enquiries:
Venn Life Sciences Holdings Plc
Allan Wood, Non-Executive Chairman Tel: +44(0)7785325898
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Davy (Nominated Adviser, ESM Adviser
and Joint Broker)
Fergal Meegan / Matthew de Vere White Tel: +353 1 679 6363
(Corporate Finance)
Hybridan LLP (Co-Broker)
Claire Louise Noyce Tel: +44(0) 20 3764 2341
Walbrook PR Ltd Tel: +44(0)20 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: +44(0) 7980 541 893
Lianne Cawthorne Mob: +44(0) 7584 391 303
About Venn Life Sciences:
Venn Life Sciences is a European Contract Research Organisation
providing drug development, clinical trial management and
resourcing solutions to pharmaceutical, biotechnology, academic and
medical device organisations. With dedicated operations in France,
Germany, the Netherlands, the UK, Ireland and Europe wide
representation - Venn specialises in tailored end to end drug
development consultancy and clinical trial management services.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAZMGZNKDVGNZM
(END) Dow Jones Newswires
July 25, 2017 02:01 ET (06:01 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024